에콰도르 급성 골수성 백혈병 약물 시장 – 2029년까지의 산업 동향 및 예측

 에콰도르 급성 골수성 백혈병 약물 시장 분석 및 통찰력

급성 골수성 백혈병(AML)은 골수에 영향을 미치는 혈액암의 한 유형입니다 . 성인에서 가장 흔한 급성 백혈병입니다. 치료하지 않으면 이 유형의 암은 일반적으로 빠르게 악화됩니다. 급성 골수성 백혈병 또는 급성 비림프구 백혈병이라고도 하는 AML은 혈액 세포에 영향을 미치는 백혈병의 한 유형입니다.

혈액 줄기 세포(미성숙 세포)는 골수에서 생성되고 시간이 지남에 따라 성숙합니다. 혈액 줄기 세포는 골수 또는 림프 줄기 세포로 분화될 수 있습니다. 백혈구는 림프 줄기 세포에서 발달합니다. 골수 줄기 세포에서 성숙한 혈액 세포는 적혈구, 과립구 및 혈소판의 세 가지 유형 중 하나입니다.

에콰도르 급성 골수성 백혈병 약물은 보조적이며 증상의 심각성을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 에콰도르 급성 골수성 백혈병 약물 시장이 2022년에서 2029년까지의 예측 기간 동안 4.5%의 CAGR로 성장할 것이라고 분석합니다.

 Ecuador Acute Myeloid Leukemia Drugs Market Dynamics

Drivers

• Rising Burden of Acute Myeloid Leukemia

The rising burden of cancer cases is one of the major boost of acute myeloid leukemia drugs. As increase in cancer cases leads to increase in demand for the treatment.

For instance,

• In Ecuador, the deaths attributed to cancer increased from 15.4% of all deaths in 2003 to 18.1% in 2016 (p<0.001)
• Between the years 2003 and 2016, almost one fifth of deaths were attributed to cancer in Ecuador

From the above point we can conclude that the incidence of acute myeloid leukemia is increasing rapidly in Ecuador and Ecuador, as a result the market of acute myeloid leukemia drugs market is also increasing. The reason of increasing cancer cases can include several factors such as changing lifestyles and environmental changes, which are expected to further boost the market growth.

• Rising Clinical Trials and Product Approval

Rising clinical trials is one of the major driver points for the market. As more clinical trials will be done, chances of new drugs approval will increase.

For instance,

• In Ecuador, from 1995 to 2019, 1996 clinical trials were done and 23.5% of them are oncological trials
• The number of oncological trials is increasing over the years with different characteristics

From the above points we can established that oncological trials are increasing in Ecuador and Ecuador over the years which is expected to drive the growth of the acute myeloid leukemia drugs market.

Opportunities

• Strategic Initiatives By Market Players

The need for medications for treatment of acute myeloid leukemia in Ecuador and Ecuador has increased due to the rise in prevalence of acute myeloid leukemia, advanced therapies for treatment of leukemia and oncology being the largest therapeutic market with unmet medical needs. These factors enhance the necessity for chemotherapy and immunotherapy and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

• In June 2020, AbbVie Inc., received the Food and Drug (FDA) approval for Venclexta (venetoclax), for the overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. Venclexta received approval, in combination with azacitidine, for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Approval was also granted in Mexico, Israel, Puerto Rico and Ecuador. The approval gained had ensured post marketing rights of venetoclax in Ecuador and its clinical use in cancer research hospitals, situated in Ecuador and Ecuador
• Rise Of Innovative Therapies

Relapse continues to be a major issue in providing cure in patients with acute myeloid leukemia (AML). The outcome after relapse is not uniform in all patients with AML and is dependent on several factors, such as age, genetic profile, cytogenetics at initial diagnosis, duration of first complete remissions. Hence, to overcome the hurdles, innovative therapies are required, with treatment strategies based on identification of specific targets and methods to overcome these aberrant processes.

For instance,

• In June 2021, Bristol Myers Squibb received the approval for Onureg (azacitidine tablets). Onureg is the first oral maintenance innovative therapy, for patients with a broad range of acute myeloid leukemia (AML) subtypes

The use of innovative therapies is expected to improve diagnosis, risk stratification, and disease monitoring of acute myeloid leukemia. The innovative combined drug therapies are expected to patient outcomes in the coming years. Hence, the use of innovative therapies is expected to create lucrative opportunity for the Ecuador and Ecuador acute myeloid leukemia drugs market.

Restraints/Challenges

However, high cost associated with the available and lack of infrastructure in low-income countries will impede the growth rate of Ecuador acute myeloid leukemia drugs market. Additionally, the risks incurred while using the orthotic devices will hinder the Ecuador acute myeloid leukemia drugs market growth. The adverse effects associated with cancer drugs and less expertise will further challenge the market in the forecast period mentioned above.

The Ecuador acute myeloid leukemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Ecuador acute myeloid leukemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

 Ecuador acute myeloid leukemia drugs is a chronic foot disorder that is relatively uncommon and whose incidence is unknown. The study by the Science Direct, states that the incidence of acute myeloid leukemia in Ecuador is 4.79 AML cases per 100,000 habitants, with the highest incidence rate observed in Piura (a coastal city in Northern Ecuador) with 38 AML cases per 100,000 habitants.

Ecuador acute myeloid leukemia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on the Ecuador Acute Myeloid Leukemia Drugs Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in the chemotherapy medication adherence during the pandemic.

Recent Development

• In June 2021, Bristol Myers Squibb had received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Ecuador and Ecuador, thereby increasing the market growth

Ecuador Acute Myeloid Leukemia Drugs Market Scope

The Ecuador acute myeloid leukemia drugs market is segmented on the basis of sub-type, drugs, drug type, and route of administration, population type end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Sub-Type

• M3 (Acute Promyelocytic Leukemia (Apl))
• M2 (Acute Myeloblastic Leukemia With Maturation)
• M4 (Acute Myelomonocytic Leukemia)
• M0 (Undifferentiated Acute Myelobastic Leukemia)
• M1 (Acute Myeloblastic Leukemia With Minimal Maturation)
• M5 (Acute Monocytic Leukemia)
• M7 (Acute Megakaryoblastic Leukemia)
• M6 (Acute Erythroid Leukemia)

On the basis of sub-type, the Ecuador acute myeloid leukemia drugs market is segmented into M0 (undifferentiated acute myelobastic leukemia), M1 (Acute myeloblastic leukemia with minimal maturation), M2 (acute myeloblastic leukemia with maturation), M3 (acute promyelocytic leukemia (APL)), M4 (acute myelomonocytic leukemia), M5 (acute monocytic leukemia), M6 (acute erythroid leukemia), M7 (acute megakaryoblastic leukemia) and M6 (acute erythroid leukemia)

Drugs

• Chemotherapy
• Targeted Therapy
• Immunotherapy

On the basis of drugs, the Ecuador acute myeloid leukemia drugs market is segmented into chemotherapy, targeted therapy, immunotherapy, and others. The chemotherapy is sub-segmented into cytosar, daunorubicin doxorubicin, methotrexate, decitabin, cladribine and others. The targeted therapy is sub segmented into venetoclax (venclexta), midostaurin (rydapt), enasidenib (idhifa) and others. The immunotherapy is sub-segmented into obinutuzumab (gazyva/gazyvaro), rituximab, interferons, alemtuzumab (campath) and others.

Drug Type

• Branded
• Generics

On the basis of drug type, the Ecuador acute myeloid leukemia drugs market is segmented into branded and generics. The branded segment is sub-segmented into cytosar, venclexta, rydapt, idhifa, gazyva/gazyvaro, campath and others.

 Route of Administration

• Oral
• Parenteral
• Others

On the basis of route of administration, the Ecuador acute myeloid leukemia drugs market is segmented into oral, parenteral and others. The oral segment is sub-segmented into tablet, capsule and others. The parenteral segment is further sub-segmented into subcutaneous, intravenous and others

Population Type

• Adult
• Geriatric
• Pediatric

On the basis of population type, the Ecuador acute myeloid leukemia drugs market is segmented into pediatric, adult and geriatric. The adults is sub-segmented into male and female.

End User

• Hospitals
• Specialty Clinics
• Ambulatory Centers
• Others

On the basis of end user, the Ecuador acute myeloid leukemia drugs market is segmented into hospitals, specialty clinics, ambulatory centers and others.

Distribution Channel

• Direct Sales
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

에콰도르 급성 골수성 백혈병 약물 시장은 유통 채널을 기준으로 직접 판매, 병원 약국, 소매 약국, 온라인 약국 및 기타로 구분됩니다.

파이프라인 분석(제공되지 않음)

• 시타라빈(3상)
• BI 836858(2단계)
• AZD5991, Venetoclax(2상)와 함께
• AZD5991(1상)
• CC-95251(1단계)
• 데시타빈(1상)
• MK-0482(1상)

에콰도르 급성 골수성 백혈병 약물 시장 지역 분석/통찰력

에콰도르 급성 골수성 백혈병 약물 시장을 분석하고, 위에 언급된 대로 국가, 하위 유형, 약물, 약물 유형, 투여 경로, 인구 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규정의 변화를 제공합니다. 신규 및 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 국내 및 국내 브랜드와의 치열한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 에콰도르 급성 골수성 백혈병 약물 시장 점유율 분석

에콰도르 급성 골수성 백혈병 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 에콰도르 급성 골수성 백혈병 약물 시장과 관련된 회사의 초점에만 관련이 있습니다.

에콰도르 급성 골수성 백혈병 약물 시장의 주요 기업으로는 Pfizer Inc., MERCK SHARP & DOHME CORP.(MERCK & CO., INC.의 자회사), Janssen Pharmaceuticals, Inc.(Johnson & Johnson Services, Inc.의 자회사), Novartis AG, Fresenius Kabi AG 및 F. Hoffmann-La Roche Ltd. 등이 있습니다.

SKU-68061